Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological and psychiatric disorders, specifically Alzheimer's disease, Major Depressive Disorder, Bipolar Disorder, and Post-Traumatic Stress Disorder. The company operates a pipeline that includes two primary drug candidates: AL001, which utilizes patented ionic cocrystal technology to deliver lithium in combination with proline and salicylate, and ALZN002, a cell-based therapeutic vaccine aimed at enhancing the immune response against Alzheimer's disease. Alzamend Neuro is headquartered in Atlanta, Georgia.
- Website
- www.alzamend.com
- Issuer profile
- All listings